Journal of Affective Disorders
June 4, 2026
Carlton M Kelly, Mathieu Fradet, Catherine Bostian et al.
Psilocybin has demonstrated promise for improving depressive symptoms in treatment-resistant depression, but its effects on anxiety, quality of life, functioning, and posttraumatic stress symptoms are less well studied. This study reports exploratory findings from an open-label trial in Veterans with TRD. Participants received a single 25-mg dose of psilocybin administered with psychological...
Journal des adolescens
June 3, 2026
Natalia Macrynikola, Jackson Doerr, Shirley Yen
INTRODUCTION Despite its known contribution to adolescent depression and suicide risk, low positive affect (PA) remains underemphasized in clinical interventions, with limited evidence on how to best enhance it. Using data from a pilot randomized controlled trial of a brief PA-enhancing intervention for high-risk youth, we hypothesized that increases in PA over the intervention period would...
ACS Medicinal Chemistry Letters
June 3, 2026
Ram W. Sabnis, Anika R. Sabnis
Provided herein are novel 5,6-bicyclic compounds as 5-HT2A receptor agonists, pharmaceutical compositions, use of such compounds in treating depression, anxiety, substance abuse and headaches, and processes for preparing such compounds.
The Journal of Clinical Psychiatry
June 3, 2026
Martin Johnson, Pau Aceves Baldo, Emilio Arbe et al.
Objective: Postpartum depression (PPD) is a debilitating mood disorder with peripartum onset. Current treatment options are limited in PPD. GH001 is a synthetic inhalation formulation of the psychoactive molecule mebufotenin (5-MeO-DMT). This trial investigated the preliminary efficacy and safety of GH001 in adult females with PPD. Methods: This phase 2a, proof-of-concept, open-label trial...
Media Keperawatan Indonesia
June 2, 2026
Siti Sarah Azzahra, Irma Nurbaeti, Puspita Palupi et al.
Menopause is a natural phase in a woman's life marked by the cessation of ovarian function and hormonal changes in estrogen and progesterone, often accompanied by physical and psychological symptoms such as anxiety, stress, and depression. One possible way to deal with these changes is to practice mindfulness, especially Islamic mindfulness, which is in line with Islamic values. This study aims...
Journal of Taibah University Medical Sciences
June 2, 2026
Danial Hasanisadr, Kaveh Rahimi, Zohreh Ghotbeddin
Background: Depression, a multifactorial psychiatric disorder, affects millions of people worldwide and has limited effective therapeutic options. This study was aimed at investigating the potential antidepressant effects of alpha-pinene (aPI) in a dextromethorphan (DEX)-induced pharmacological model in rats. Methods: Thirty-two adult male Wistar rats were randomly assigned to four groups (n =...
Indian Journal of Psychological Medicine
June 2, 2026
Nikapitiye Nandarathana, Jay Kumar Ranjan
correction
[This corrects the article DOI: 10.1177/02537176241249375.].
European Psychiatry
June 1, 2026
P.-M. Llorca, Ludovic Samalin, Emilie Olié et al.
Introduction: Esketamine nasal spray (ESK) was approved in 2019 in Europe for adults with Treatment-Resistant Depression (TRD), defined as inadequate response to at least two different antidepressants during the current moderate to severe depressive episode Objectives: To assess patient-reported outcomes related to symptomatology, quality of life, and occupational impairment over 12 months...
European Psychiatry
June 1, 2026
E. Saez, M. Gómez-Revuelta, O. Olivas et al.
Introduction The glutamatergic system is implicated in the pathogenesis of Treatment Resistant Depression (TRD), evidenced by the efficacy of ketamine, a N-methyl-D-aspartate receptor (NMDAR) antagonist. This hypothesis suggests that NMDAR inhibition promotes glutamate release via suppression of NMDAR GABAergic interneurons (1). Studies report reduced plasmatic Gamma AminoButiric Acid (pGABA)...
European Psychiatry
June 1, 2026
V. Casati, Kevin la Monica, Mauro Angeletti et al.
Introduction Intranasal esketamine has emerged as an innovative treatment for TRD due to its rapid antidepressant effects. However, the clinical response is heterogeneous, and growing evidence suggests that comorbid personality disorders (PDs) may significantly shape treatment outcomes. Although PDs are frequently diagnosed in TRD patients, little is known about their differential influence on...